Targeting STAT3 and MEK/ERK/BCL2 activity by specific inhibitors resulted in significant MM cell death and growth inhibition and their combinations had a synergistic cytotoxic effect on myeloma cells. The gene discussed is STAT3; the disease is Miyoshi myopathy.